The fed­er­al gov­ern­ment has on­ly sent four ship­ments of Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir (about 400,000 cours­es in each ship­ment) na­tion­wide, and al­ready HHS is re­port­ing … ...

Amerisource­Ber­gen earned a whop­ping $60.1 bil­lion last quar­ter, thanks in part to its dis­tri­b­u­tion of gov­ern­ment-owned Covid treat­ments. Now it’s time to rein­vest some of … ...

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) ...

Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

As Pfiz­er and BioN­Tech tout the ef­fec­tive­ness of their bi­va­lent boost­er against Omi­cron vari­ants such as BA.4 and BA.5, more Covid-19 vari­ants have been creep­ing … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther ...

In the midst of their $500 mil­lion pro­gram to build a Covid-19 vac­cine with BioN­Tech, Pfiz­er has an­nounced a siz­able deal to com­mer­cial­ize a … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.